What Should a SARMs Certificate of Analysis Contain Before a Lot Is Accepted?
A usable SARMs certificate of analysis is a controlled record, not a marketing panel. Before any purity figure is read, the header should name the issuing laboratory, the sample identifier, the analysis date, and a lot code that matches the container label without interpolation. The identity block should carry a specific compound name, not the class label alone. Where a CAS registry number, molecular formula and monoisotopic mass are stated, they should agree. A mismatch between formula and mass is a documentation defect even if the purity cell looks acceptable. Specification and result should sit in separate columns. A result without a limit cannot be reviewed, and a limit without a method identifier cannot be reproduced. Method fields for a small-molecule CoA include technique, column or method code, detection mode and, where mass spectrometry is claimed, ionisation mode and the ion regarded as diagnostic. An accreditation claim should name the accredited entity and the scope in enough detail to be checked. A logo is not a scope. Sign-off should show who reviewed the file and when. Undated files, files reused across lots, and files whose sample name is a product family rather than a lot are incomplete for intake. The reporting basis must be explicit. Area-normalised chromatographic purity, an external-standard assay and a qualitative identity test are different measurements and must not be collapsed into one percentage. If the basis is omitted, the percentage is not interpretable. Keep the certificate with the purchase record and the container identifier so a later audit can reconstruct which document belonged to which vial.
How Is the Named SARM Identified, Rather Than Only Classified?
Selective androgen receptor modulators are not one molecule. The class name covers distinct small-molecule chemotypes that control methods are built to separate. A certificate that reports only "SARM", a blend name, or a laboratory nickname has not identified the analyte. The identity statement should use a systematic or otherwise traceable name, and that name should be stable across the header, the chromatogram sample line and the mass-spectrometry caption. Reviewers should check that the stated molecular formula is arithmetically consistent with the stated monoisotopic mass, within ordinary rounding. If a salt or counter-ion is part of the supplied solid, the certificate should say whether the formula refers to the free molecule or the salt. Leaving that distinction blank makes later analytical calculations ambiguous. Stereochemistry belongs in the identity block when the structure has a defined configuration. A racemate and a single enantiomer are different research materials. Chemical purity by reversed-phase HPLC does not establish enantiomeric composition. That question needs a chiral method or another orthogonal record, and the certificate should not imply that an achiral chromatogram answered it. Mass evidence should agree with the named structure rather than with a neighbour in the same class. Published detection work regards individual SARMs as separate analytes, which is why a class label fails as identity (Thevis et al., 2018). Later work on advances in that field continues to place structural specificity at the centre of the analytical problem (Slíž et al., 2025). A 2018 review frames the subject as a defined chemical class in the analytical literature, not as an undifferentiated powder (Miklos, 2018). Identity review stops at structure and records. A useful identity block also states the physical form received, such as neat solid or a stated solution, so the formula being checked is the formula of the named analyte rather than an unstated mixture. Where two names appear, the reviewer should record which name is systematic and which is a laboratory alias, and should not treat the alias as a second structure unless a second formula and mass are supplied.
How Should Chromatographic Purity and Related-Substance Rows Be Read?
Area-normalised purity is the figure most often misread on a small-molecule certificate. It is the main-peak area divided by the sum of integrated peak areas under a stated method, usually as a percentage. It is not an assay, not a mass balance, and not a statement of how much of the vial is the named compound. Residual solvent, water, inorganic residue and counter-ion can all sit outside the ultraviolet chromatogram. A file that reports a high purity figure and is silent on those orthogonal tests has characterised the chromatogram, not the solid. The method line should state detection wavelength or detector type, because different wavelengths change relative peak areas when impurities and the main component do not share a chromophore. A value copied from an unspecified wavelength cannot be compared with another lot. Related-substance rows should list retention time or relative retention time, area percent, and a class such as specified impurity, unspecified impurity or unidentified. Peaks below a reporting threshold may be omitted only if that threshold is declared. If no threshold is declared, a clean table may mean that small peaks were not integrated. Co-elution inflates area-percent purity, so resolution and peak shape belong in the review when the main peak is broad, split or poorly separated from a neighbour. System-suitability results, where provided, should be read before the sample result. A failing suitability run leaves the sample percentage unsupported. Manual baseline edits, dropped peaks, or a peak table that does not add to the stated purity are reasons to request the chromatogram. An unreconciled peak table should be queried before the lot is compared with any other file.
When Does Mass Spectrometry Confirm the Named Structure?
Mass spectrometry on a SARMs certificate is useful only when the observed ion is compared with a calculated mass for the named structure, under a stated ionisation mode and charge state. A printed spectrum without an assignment is an image, not a result. For electrospray records, reviewers should look for the diagnostic ion, often a protonated molecule for these small compounds, and a mass error in daltons or parts per million against the calculated value. The acceptance window should be the laboratory's own window, written on the certificate, not a window invented by the reader. In-source fragments can be mistaken for impurities, and impurities can be mistaken for fragments. The certificate should say which signals were assigned to the main component and which were left unidentified. Tandem spectra add structural evidence if product ions are consistent with the proposed structure and the precursor is the same ion used in the intact-mass check. A product-ion list copied from a public spectrum, without a sample identifier, does not tie the pattern to the lot. Chromatography coupled to mass spectrometry is stronger than direct infusion when related substances are in scope, because retention time and mass are paired. Direct infusion can show that an ion of the expected mass is present. It cannot show that the ultraviolet main peak is that ion. Concordance means the chromatographic main peak, the assigned ion and the header name describe one sample. If any of the three points to a different compound, the lot fails identity review regardless of the purity percentage. Assign the ion on the certificate; do not leave the reader to infer it from an unlabelled plot.
How Should Lot Traceability and the Limits of a Supplier CoA Be Judged?
A correct result on the wrong container is a failed record. The lot code on the certificate, the chromatogram header, the mass-spectrometry sample list and the label should match exactly, including prefixes and hyphens. Near matches are mismatches. A chromatogram dated far from the certificate, or a spectrum file named for another product, breaks the chain. Spreadsheets pasted into a PDF, purity values with no peak table, and chromatograms lacking instrument and method identifiers are weaker than controlled data exports. Reviewer initials and a review date support attributability. Nominal concentration, diluent and chromatographic load volume should be stated when peak shape is in question; their absence is a gap, not a licence to guess. One certificate covers multiple vials only when the supplier states that the tested sample represents that lot. A second lot needs a second record. Storage lines are label text unless a study identifier is cited. Traceability is not regulatory status. Detection literature shows that SARMs are targeted as distinct named analytes, and that this analytical field has continued to develop (Thevis et al., 2018; Slíž et al., 2025). A 2018 review places the class in a defined analytical framework rather than treating it as an undifferentiated powder (Miklos, 2018). None of those papers turns a supplier PDF into an accredited laboratory result. A 2026 notice records unapproved status for products in this class, so a purity figure does not clear that status (Reactions Weekly, 2026). Mancin et al. (2026) is a separate documentary source and does not authenticate a research-chemical lot. The transferable point is documentary caution only: a label is not self-proving, and that source does not replace chromatogram review, mass assignment or lot matching. Australian research files should accept or reject the package on identity, purity basis, mass agreement and lot match, and should state that the material is for laboratory research and is not for human use. The archive note should also record the purity basis in the supplier's own words, the ionisation mode if mass data are present, and whether formula and monoisotopic mass were checked arithmetically. Those notes keep the decision inside analytical chemistry and lot documentation. A later reader should be able to see which file was accepted, which comparison failed, and which raw export was missing, without reconstructing the review from memory.
Frequently asked questions
What should a laboratory use a SARMs certificate of analysis for?
A SARMs certificate of analysis is a lot record of identity and purity data for a named research chemical. Use it to test header, chromatogram and mass concordance before the file is archived. It is not an approval. The material is not for human use.
Is chromatographic purity the same as an assay result?
No. Area-normalised purity is the main-peak share of integrated peaks under a stated method. An assay estimates how much of the named compound is in the solid and can diverge when water, solvent or counter-ion sit outside the chromatogram. If the basis is unstated, do not compare the percentage across lots.
Why is a class label not enough identity for a SARM lot?
The class contains distinct small molecules. Detection work regards individual SARMs as separate analytes, so a class label or nickname does not identify the lot (Thevis et al., 2018). Require a traceable compound name that agrees with the formula, the mass assignment and the chromatogram sample line.
Which traceability failures should keep a certificate out of the archive?
Quarantine the lot when the lot code is not identical on the label, the certificate, the chromatogram and the mass sample list. Also hold the file if it is undated, if the spectrum name points to another product, or if the peak table does not support the stated purity. A second lot needs its own record.
Can detection papers or a purity figure replace a regulatory determination?
No. Published advances in the analytical literature describe detection work on named analytes; they do not authenticate a supplier PDF (Slíž et al., 2025). A 2026 notice on unapproved status in this class is not lifted by a purity cell (Reactions Weekly, 2026). Confirm legal status separately. A certificate is not an approval, and the material is not for human use.
References
- DOI:10.1016/j.mce.2017.01.040 — Detection of SARMs in doping control analysis — Molecular and Cellular Endocrinology — 2018
- DOI:10.1002/dta.3697 — Advances in SARMs anti‐doping analysis — Drug Testing and Analysis — 2025
- DOI:10.31925/farmacia.2018.5.3 — SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMs) IN THE CONTEXT OF DOPING — FARMACIA — 2018
- DOI:10.1007/s40278-026-95124-7 — Unapproved peptide products and SARMs pose risks — Reactions Weekly — 2026
- PMID:42639281 — Reducing the Risk of Unintentional Doping From Supplements: A Practical Guide for Athletes and Support Teams — Transl Sports Med — 2026
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
